1. Generics Bulletin
  2. >>Products
  3. >>Value Added Medicines

Hyloris Submits Additional Data For Maxigesic IV Filing To US FDA

Firm Received Pushback From FDA On Product’s Packaging

 
• By Chloe Kent

Hyloris has submitted additional data to the US Food and Drug Administration about its value-added analgesic Maxigesic IV, following enquiries about potential extractable and leachable compounds expected to be present in the product due to the packaging.

Entrance to FDA headquarters in Maryland
The FDA had additional questions about the vial and stopper of the Maxigesic IV packaging • Source: Alamy

Belgian value-added medicines firm Hyloris and its development partner AFT Pharmaceuticals have submitted additional data to the US Food and Drug Administration regarding its 505(b)(2) hybrid application for Maxigesic IV (paracetamol/ibuprofen) 1,000mg/300mg. The application was knocked back by the FDA last year when it requested additional information about the dual mode-of-action intravenous pain treatment.

The submission of Hyloris’ “additional extractable & leachable data set” followed a complete response letter received in July 2022 regarding...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Value Added Medicines

The Generics Bulletin Podcast: The Global Generics & Biosimilars Awards 2025

 
• By Dave Wallace and Dean Rudge

With entries now open for the Global Generics & Biosimilars Awards 2025 – which takes place in Frankfurt on Wednesday 29 October – Generics Bulletin’s editors discuss all the key details, including tips for entrants, in our latest podcast.

‘Why Wouldn’t You Use This?’: Teva Plots $2bn LAI Schizophrenia Franchise

 
• By Dean Rudge

Teva has laid out an ambitious goal for its long-acting injectable schizophrenia drugs to grow into a $2bn franchise, ahead of the planned US filing of olanzapine later this year.

Fresenius Adds To Denosumab Competitors In Europe

 
• By Dave Wallace

At a busy meeting of the CHMP, the EMA issued positive opinions for Fresenius Kabi’s denosumab rivals to Prolia and Xgeva, another denosumab biosimilar from Sandoz, a Tecfidera hybrid from Neuraxpharm and a Descovy generic from Viatris. Meanwhile, Ascend has withdrawn a teriparatide filing.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

More from Products